Health Care [ 5/12 ] | Pharmaceuticals [ 13/73 ]
NASDAQ | Common Stock
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
The company operates through two segments, Animal Health and Human Health.
It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea.
The company is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -10.26 Decreased by -153.96% | -0.28 Decreased by -3.56 K% |
| May 12, 25 | -18.77 Decreased by -26.72 K% | -10.82 Decreased by -73.50% |
| Mar 31, 25 | -125.80 Decreased by -281.21% | -18.50 Decreased by -580.00% |
| Nov 12, 24 | -1.05 Decreased by -90.91% | -2.37 Increased by +55.70% |
| Aug 13, 24 | -4.04 Decreased by -485.51% | -1.20 Decreased by -236.67% |
| May 14, 24 | -0.07 Increased by +97.07% | -0.03 Decreased by -133.33% |
| Jan 31, 24 | -33.00 Decreased by -862.18% | -73.80 Increased by +55.28% |
| Nov 14, 23 | -0.55 Increased by +93.89% | -1.23 Increased by +55.28% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 2.98 M Increased by +9.48% | -10.41 M Decreased by -9.64% | Decreased by -349.35% Decreased by -0.14% |
| Mar 31, 25 | 2.17 M Decreased by -7.66% | -10.46 M Decreased by -13.42% | Decreased by -481.99% Decreased by -22.82% |
| Dec 31, 24 | 3.51 M Increased by +24.74% | -9.92 M Decreased by -27.54% | Decreased by -282.70% Decreased by -2.24% |
| Sep 30, 24 | 3.11 M Increased by +16.14% | -9.85 M Increased by +18.90% | Decreased by -317.05% Increased by +30.17% |
| Jun 30, 24 | 2.72 M Increased by +37.98% | -9.49 M Increased by +22.21% | Decreased by -348.84% Increased by +43.62% |
| Mar 31, 24 | 2.35 M Decreased by -27.88% | -9.23 M Decreased by -25.01% | Decreased by -392.43% Decreased by -73.35% |
| Sep 30, 23 | 2.81 M Decreased by -10.70% | -7.78 M Increased by +37.88% | Decreased by -276.50% Increased by +30.43% |
| Jun 30, 23 | 2.68 M Decreased by -8.39% | -12.15 M Decreased by -29.71% | Decreased by -454.04% Decreased by -41.59% |